Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Biotechnology 26, 1095 (1 October 2008) | doi:10.1038/nbt1008-1095
Research Highlights
Abstract
Lymphoma therapy with a BiTE Bargou et al. have provided the first clinical evidence for the cytotoxic potential of very low doses of a bispecific T-cell 'engager' (BiTE) single-chain antibody to stimulate an individual's T cells against non-Hodgkin's B-cell lymphoma. Previous studies involving mouse models demonstrated that blinatumomab, a BiTE with dual specificity for CD19 (a differentiation antigen expressed on almost all B cell lymphomas and leukemias) and CD3 (an invariant T-cell receptor), activates resting T cells to serially lyse cancer cells.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
